Safety profiles of CAR-T cell therapy in systematic autoimmune diseases: a systematic review and analysis.
Immunol ResSep 8, 2026 (epub)
Yan Xie, Yang Liu, Xiaoyuan Chen et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review analyzed the safety profiles of CAR-T cell therapy in 115 patients with autoimmune diseases. The study found that severe adverse events were rare, with cytokine release syndrome (CRS) occurring in 70.4% of patients, primarily low-grade. The review highlights the need for further research to confirm these findings.
Key findings
- Cytokine release syndrome (CRS) occurred in 70.4% of patients, mostly low-grade.
- Immune effector cell-associated neurotoxicity syndrome (ICANS) was observed in 4.3% of patients.
- Infections were reported in nearly half of the patients, but severe infections were infrequent.
- BCMA-targeted therapy and allogeneic CAR-T products were associated with a reduced risk of CRS.
Why it matters
Understanding the safety profiles of CAR-T therapy in autoimmune diseases is crucial for clinicians considering this treatment option. The findings suggest that while adverse events can occur, they are generally manageable, which may encourage further exploration of CAR-T therapy in this population.